These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A New Beginning for Triglyceride-Lowering Therapies. Pradhan AD Circulation; 2019 Jul; 140(3):167-169. PubMed ID: 30836784 [No Abstract] [Full Text] [Related]
5. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517 [TBL] [Abstract][Full Text] [Related]
6. Triglyceride as a risk factor for coronary artery disease. Gotto AM Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100 [TBL] [Abstract][Full Text] [Related]
7. Hypertriglyceridemia as a possible independent risk factor for stroke. Lisak M; Demarin V; Trkanjec Z; Basić-Kes V Acta Clin Croat; 2013 Dec; 52(4):458-63. PubMed ID: 24696996 [TBL] [Abstract][Full Text] [Related]
8. Combination lipid therapy in type 2 diabetes. Saely CH; Rein P; Drexel H N Engl J Med; 2010 Aug; 363(7):692; author reply 694-5. PubMed ID: 20701533 [No Abstract] [Full Text] [Related]
10. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Arbel Y; Klempfner R; Erez A; Goldenberg I; Benzekry S; Shlomo N; Fisman EZ; Tenenbaum A; Cardiovasc Diabetol; 2016 Jan; 15():11. PubMed ID: 26794137 [TBL] [Abstract][Full Text] [Related]
11. Serum triglycerides and clinical benefit in lipid-lowering trials. Kesäniemi YA Am J Cardiol; 1998 Feb; 81(4A):70B-73B. PubMed ID: 9526818 [TBL] [Abstract][Full Text] [Related]
12. Drugs for hypertriglyceridemia. Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119 [No Abstract] [Full Text] [Related]
13. Atherogenic dyslipidemia in the cardiometabolic syndrome. Govindarajan G; Chowdhury N; Flaker G J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818 [No Abstract] [Full Text] [Related]
14. [Serum triglycerides as a risk factor for atherosclerosis]. Stalenhoef AF Ned Tijdschr Geneeskd; 1999 Feb; 143(6):284-7. PubMed ID: 10221081 [TBL] [Abstract][Full Text] [Related]
15. [Lipometabolic disorder--cholesterol and triglycerides]. Luley C Clin Res Cardiol; 2006; 95 Suppl 6():VI17-22. PubMed ID: 17013580 [TBL] [Abstract][Full Text] [Related]
18. Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease. Sprecher DL; Watkins TR; Behar S; Brown WV; Rubins HB; Schaefer EJ Am J Cardiol; 2003 Mar; 91(5):575-80. PubMed ID: 12615263 [No Abstract] [Full Text] [Related]
19. [Residual risk: The roles of triglycerides and high density lipoproteins]. Grammer T; Kleber M; Silbernagel G; Scharnagl H; März W Dtsch Med Wochenschr; 2016 Jun; 141(12):870-7. PubMed ID: 27305303 [TBL] [Abstract][Full Text] [Related]
20. Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis. van Wijk JP; Halkes CJ; De Jaegere PP; Plokker HW; Erkelens DW; Cabezas MC Atherosclerosis; 2003 Nov; 171(1):109-16. PubMed ID: 14642412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]